Daclizumab: Outcome of phase III trials and mechanism of action

被引：59

作者：

Vincenti, F

Nashan, B

Light, S

机构：

[1] Univ Calif San Francisco, Kidney Transplant Serv, San Francisco, CA 94143 USA

[2] Med Hsch Hannover, Klin Abdominal & Transplantat Chirurg, Hannover, Germany

[3] Hoffmann LaRoche, Nutley, NJ USA

来源：

TRANSPLANTATION PROCEEDINGS | 1998年 / 30卷 / 05期

关键词：

D O I：

10.1016/S0041-1345(98)00571-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2155 / 2158

页数：4

共 5 条

[1]

GELDER T, 1995, TRANSPLANTATION, V60, P248

[2] A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL-ANTIBODY IN HUMAN RENAL-TRANSPLANTATION [J].

KIRKMAN, RL ;

SHAPIRO, ME ;

CARPENTER, CB ;

MCKAY, DB ;

MILFORD, EL ;

RAMOS, EL ;

TILNEY, NL ;

WALDMANN, TA ;

ZIMMERMAN, CE ;

STROM, TB .

TRANSPLANTATION, 1991, 51 (01) :107-113

[3] RANDOMIZED CONTROLLED TRIAL OF A MONOCLONAL-ANTIBODY AGAINST THE INTERLEUKIN-2 RECEPTOR (33B3.1) AS COMPARED WITH RABBIT ANTITHYMOCYTE GLOBULIN FOR PROPHYLAXIS AGAINST REJECTION OF RENAL-ALLOGRAFTS [J].

SOULILLOU, JP ;

CANTAROVICH, D ;

LEMAUFF, B ;

GIRAL, M ;

ROBILLARD, N ;

HOURMANT, M ;

HIRN, M ;

JACQUES, Y .

NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (17) :1175-1182

[4]

STOCK PG, 1996, TRANSPLANT P, V88, P925

[5] A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation [J].

Vincenti, F ;

Lantz, M ;

Birnbaum, J ;

Garovoy, M ;

Mould, D ;

Hakimi, J ;

Nieforth, K ;

Light, S .

TRANSPLANTATION, 1997, 63 (01) :33-38

← 1 →